- Home
- DOCU vs JAZZ Comparison
DOCU vs JAZZ Comparison
Compare DOCU & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCU | JAZZ |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 16.1B |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DOCU | JAZZ |
|---|---|---|
| Price | $81.07 | $242.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 19 | 22 |
| Target Price | $71.93 | ★ $296.77 |
| AVG Volume (30 Days) | ★ 2.3M | 745.1K |
| Earning Date | 12-03-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.80 | 0.04 |
| Revenue | ★ $3,219,500,000.00 | $1,618,693,000.00 |
| Revenue This Year | $8.86 | $12.57 |
| Revenue Next Year | $8.00 | $5.14 |
| P/E Ratio | ★ $100.48 | $6,059.13 |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $40.16 | $156.95 |
| 52 Week High | $85.90 | $266.38 |
Technical Indicators
Market Signals| Indicator | DOCU | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 60.04 | 61.88 |
| Support Level | $42.89 | $236.70 |
| Resistance Level | $85.90 | $250.49 |
| Average True Range (ATR) | 2.71 | 7.34 |
| MACD | -0.58 | 3.76 |
| Stochastic Oscillator | 60.17 | 84.08 |
Price Performance
Historical ComparisonAbout DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.